Snehal Patel Buys 2,500 Shares of Greenwich LifeSciences (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel purchased 2,500 shares of the firm’s stock in a transaction dated Thursday, July 23rd. The stock was purchased at an average cost of $13.14 per share, for a total transaction of $32,850.00. Following the acquisition, the chief executive officer owned 5,606,602 shares of the company’s stock, valued at approximately $73,670,750.28. This trade represents a 0.04% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Snehal Patel also recently made the following trade(s):

• On Monday, July 27th, Snehal Patel acquired 1,500 shares of Greenwich LifeSciences stock. The shares were acquired at an average cost of $13.62 per share, with a total value of $20,430.00.
• On Friday, July 24th, Snehal Patel acquired 1,100 shares of Greenwich LifeSciences stock. The shares were acquired at an average cost of $12.88 per share, with a total value of $14,168.00.

Greenwich LifeSciences Stock Down 5.1%

Greenwich LifeSciences stock opened at $12.77 on Thursday. The stock has a market cap of $187.46 million, a price-to-earnings ratio of -8.13 and a beta of 1.40. The business has a 50-day simple moving average of $21.34 and a 200 day simple moving average of $24.20. Greenwich LifeSciences, Inc. has a 52 week low of $7.78 and a 52 week high of $34.10.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Marshall Wace LLP bought a new stake in Greenwich LifeSciences in the 2nd quarter worth $509,000. Bank of New York Mellon Corp boosted its holdings in shares of Greenwich LifeSciences by 235.5% during the first quarter. Bank of New York Mellon Corp now owns 46,523 shares of the company’s stock worth $1,117,000 after purchasing an additional 32,657 shares during the period. Virtu Financial LLC bought a new stake in shares of Greenwich LifeSciences in the fourth quarter worth about $605,000. Man Group plc purchased a new position in Greenwich LifeSciences during the 4th quarter valued at about $590,000. Finally, Sei Investments Co. purchased a new position in Greenwich LifeSciences during the 1st quarter valued at about $627,000. Institutional investors own 4.16% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. HC Wainwright boosted their price objective on Greenwich LifeSciences from $50.00 to $69.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Greenwich LifeSciences in a research note on Friday, May 15th. Finally, Wall Street Zen lowered shares of Greenwich LifeSciences from a “hold” rating to a “sell” rating in a research report on Saturday, June 6th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Greenwich LifeSciences currently has an average rating of “Hold” and an average target price of $57.00.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.